Igor V. Samoylenko

Moscow, MOW 115478, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Squamous Cell Carcinoma of the Skin in a Teenager with Fanconi Anemia: A Challenging Treatment.

Squamous Cell Carcinoma of the Skin in a Teenager with Fanconi Anemia: A Challenging Treatment.

Journal: International journal of molecular sciences

Published: March 20, 2026

The Efficacy of Electronic Health Record-Based Artificial Intelligence Models for Early Detection of Pancreatic Cancer: A Systematic Review and Meta-Analysis.

The Efficacy of Electronic Health Record-Based Artificial Intelligence Models for Early Detection of Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Journal: Cancers

Published: December 23, 2025

Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674].

Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674].

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 31, 2025

Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial.

Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 15, 2025

FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma.

FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma.

Journal: Journal for immunotherapy of cancer

Published: March 10, 2025

Systematic evaluation of intratumoral and peripheral BCR repertoires in three cancers.

Systematic evaluation of intratumoral and peripheral BCR repertoires in three cancers.

Journal: eLife

Published: January 20, 2025

Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma.

Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma.

Journal: Journal for immunotherapy of cancer

Published: November 24, 2024

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study.

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study.

Journal: Frontiers in oncology

Published: March 03, 2024

Pinpointing the tumor-specific T cells via TCR clusters.

Pinpointing the tumor-specific T cells via TCR clusters.

Journal: eLife

Published: January 22, 2022

Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE).

Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE).

Journal: Cancers

Published: April 06, 2021

Screening for Melanoma and Other Skin Cancer Shows a Higher Early Melanoma Incidence: Social Educational Program "Life Fear-Free".

Screening for Melanoma and Other Skin Cancer Shows a Higher Early Melanoma Incidence: Social Educational Program "Life Fear-Free".

Journal: Dermatopathology (Basel, Switzerland)

Published: February 12, 2021

Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.

Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.

Journal: Journal for immunotherapy of cancer

Published: January 10, 2021

Showing 1-12 of 14

Last Updated: 09/26/2026